The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
作者信息
Ma Qinhai, Qiu Minshan, Zhou Hongxia, Chen Jie, Yang Xue, Deng Zhenxuan, Chen Liping, Zhou Jinchao, Liao Yuping, Chen Qimin, Zheng Qianwei, Cai Lihua, Shen Lihan, Yang Zifeng
机构信息
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Dongguan People's Hospital, Dongguan, 523059, PR China.
出版信息
Pharmacol Res. 2020 Oct;160:105073. doi: 10.1016/j.phrs.2020.105073. Epub 2020 Jul 9.
Abstract
摘要
相似文献
1
The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
Pharmacol Res. 2020 Oct;160:105073. doi: 10.1016/j.phrs.2020.105073. Epub 2020 Jul 9.
2
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
Signal Transduct Target Ther. 2020 May 8;5(1):66. doi: 10.1038/s41392-020-0176-0.
3
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
Pharmacol Res. 2020 Aug;158:104929. doi: 10.1016/j.phrs.2020.104929. Epub 2020 May 20.
4
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Biochem Pharmacol. 2020 Oct;180:114169. doi: 10.1016/j.bcp.2020.114169. Epub 2020 Jul 23.
5
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
6
The pros and cons of traditional Chinese medicines in the treatment of COVID-19.
Pharmacol Res. 2020 Jul;157:104873. doi: 10.1016/j.phrs.2020.104873. Epub 2020 May 3.
7
Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
Ann Palliat Med. 2020 Sep;9(5):3235-3248. doi: 10.21037/apm-20-1478. Epub 2020 Sep 10.
8
SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
Travel Med Infect Dis. 2020 Sep-Oct;37:101685. doi: 10.1016/j.tmaid.2020.101685. Epub 2020 Apr 22.
9
Purposing Saikosaponins for the treatment of COVID-19.
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
10
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9.
引用本文的文献
1
Treatment effects of Xuebijing injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial.
EClinicalMedicine. 2025 Jul 9;86:103341. doi: 10.1016/j.eclinm.2025.103341. eCollection 2025 Aug.
2
A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With "Long-Covid-19".
Pulm Circ. 2025 Apr 27;15(2):e70084. doi: 10.1002/pul2.70084. eCollection 2025 Apr.
3
Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19.
Front Med. 2023 Dec;17(6):1014-1029. doi: 10.1007/s11684-023-1040-8. Epub 2023 Dec 29.
4
Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets.
Pharm Biol. 2023 Dec;61(1):1186-1210. doi: 10.1080/13880209.2023.2241518.
5
Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Metaanalysis.
J Tradit Chin Med. 2023 Aug;43(4):631-639. doi: 10.19852/j.cnki.jtcm.20230517.002.
6
Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.
Acta Pharm Sin B. 2023 Jun 5;13(9):3598-637. doi: 10.1016/j.apsb.2023.06.001.
7
New opportunities and challenges of natural products research: When target identification meets single-cell multiomics.
Acta Pharm Sin B. 2022 Nov;12(11):4011-4039. doi: 10.1016/j.apsb.2022.08.022. Epub 2022 Aug 27.
8
Traditional Chinese medicine injections: where we are after 80-year development.
Chin Med. 2022 Nov 8;17(1):127. doi: 10.1186/s13020-022-00681-w.
9
Exploring primary healthcare practitioners' experiences regarding the coronavirus disease 2019 (COVID-19) pandemic in KwaZulu-Natal, South Africa.
Prim Health Care Res Dev. 2022 Nov 4;23:e67. doi: 10.1017/S1463423622000536.
10
Role of Traditional Chinese Medicine in Treating Severe or Critical COVID-19: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Front Pharmacol. 2022 Jul 15;13:926189. doi: 10.3389/fphar.2022.926189. eCollection 2022.
本文引用的文献
1
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
4
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
5
XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
Crit Care Med. 2019 Sep;47(9):e735-e743. doi: 10.1097/CCM.0000000000003842.
6
Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation.
Evid Based Complement Alternat Med. 2014;2014:949254. doi: 10.1155/2014/949254. Epub 2014 Mar 23.
7
Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.
Lancet Infect Dis. 2013 Sep;13(9):752-61. doi: 10.1016/S1473-3099(13)70204-4. Epub 2013 Jul 26.
Zotero 插件